The AIDS Clinical Trials Group (ACTG) has presented significant data from the REPRIEVE experiment in an article published in the New England Journal of Medicine. The experiment aimed to prevent cardiovascular disease in HIV-positive people. Participants who took pitavastatin calcium, a daily cholesterol-lowering statin medication, had a 35% decreased risk of serious adverse cardiovascular events when compared to those who got a placebo. The experiment included 7,769 people from different nations and demographics. It is worth noting that the reduction in cardiovascular events was uniform across all research groups. Pitavastatin was well tolerated, with just minor muscle-related side effects. Because of the good results, an Independent Data and Safety Monitoring Board decided to discontinue the experiment early. This study provides data to support the use of statins in persons who have type 2 diabetes.

To know more: About the original article click here.